{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:25Z","timestamp":1787020885302,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["Bristol Myers Squibb provided the study drug and an unrestricted research grant."],"award-info":[{"award-number":["Bristol Myers Squibb provided the study drug and an unrestricted research grant."]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1364-3","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T07:17:41Z","timestamp":1499239061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis"],"prefix":"10.1186","volume":"19","author":[{"given":"Agnes","family":"Szentpetery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gogarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Mellerick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaab","family":"Elmamoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"1364_CR1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/ar2580","volume":"11","author":"O Fitzgerald","year":"2009","unstructured":"Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther. 2009;11:214.","journal-title":"Arthritis Res Ther"},{"key":"1364_CR2","doi-asserted-by":"crossref","unstructured":"Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol. 2016;12:406\u201316.","DOI":"10.1586\/1744666X.2016.1139453"},{"key":"1364_CR3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.autrev.2014.11.012","volume":"14","author":"M Diani","year":"2015","unstructured":"Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;14:286\u201392.","journal-title":"Autoimmun Rev"},{"key":"1364_CR4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/cmi.2012.15","volume":"9","author":"Y Cai","year":"2012","unstructured":"Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9:302\u20139.","journal-title":"Cell Mol Immunol"},{"key":"1364_CR5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O FitzGerald","year":"2015","unstructured":"FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17:115.","journal-title":"Arthritis Res Ther"},{"key":"1364_CR6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/art.30173","volume":"63","author":"DJ Veale","year":"2011","unstructured":"Veale DJ. New therapies and new goals for psoriatic arthritis. Arthritis Rheum. 2011;63:874\u20136.","journal-title":"Arthritis Rheum"},{"key":"1364_CR7","first-page":"S20","volume":"33","author":"M Mortezavi","year":"2015","unstructured":"Mortezavi M, Thiele R, Ritchlin C. The joint in psoriatic arthritis. Clin Exp Rheumatol. 2015;33:S20\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"1364_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fimmu.2015.00061","volume":"6","author":"RE Hoeppli","year":"2015","unstructured":"Hoeppli RE, Wu D, Cook L, Levings MK. The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome. Front Immunol. 2015;6:61.","journal-title":"Front Immunol"},{"key":"1364_CR9","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.3899\/jrheum.110377","volume":"38","author":"H Appel","year":"2011","unstructured":"Appel H, Wu P, Scheer R, Kedor C, Sawitzki B, Thiel A, et al. Synovial and peripheral blood CD4\u2009+\u2009FoxP3+ T cells in spondyloarthritis. J Rheumatol. 2011;38:2445\u201351.","journal-title":"J Rheumatol"},{"key":"1364_CR10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0463.2011.02848.x","volume":"120","author":"LR Ryder","year":"2012","unstructured":"Ryder LR, Bartels EM, Woetmann A, Madsen HO, Odum N, Bliddal H, et al. FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis. APMIS. 2012;120:387\u201396.","journal-title":"APMIS"},{"key":"1364_CR11","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.0806855105","volume":"105","author":"F Flores-Borja","year":"2008","unstructured":"Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2008;105:19396\u2013401.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1364_CR12","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1136\/ard.2008.100768","volume":"68","author":"S Raghavan","year":"2009","unstructured":"Raghavan S, Cao D, Widhe M, Roth K, Herrath J, Engstrom M, et al. FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. Ann Rheum Dis. 2009;68:1908\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1364_CR13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","volume":"174","author":"H Sugiyama","year":"2005","unstructured":"Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, et al. Dysfunctional blood and target tissue CD4+\u2009CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174:164\u201373.","journal-title":"J Immunol"},{"key":"1364_CR14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2011.200","volume":"131","author":"DC Soler","year":"2011","unstructured":"Soler DC, McCormick TS. The dark side of regulatory T cells in psoriasis. J Invest Dermatol. 2011;131:1785\u20136.","journal-title":"J Invest Dermatol"},{"key":"1364_CR15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5021\/ad.2010.22.4.397","volume":"22","author":"WJ Yun","year":"2010","unstructured":"Yun WJ, Lee DW, Chang SE, Yoon GS, Huh JR, Won CH, et al. Role of CD4CD25FOXP3 regulatory T cells in psoriasis. Ann Dermatol. 2010;22:397\u2013403.","journal-title":"Ann Dermatol"},{"key":"1364_CR16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","volume":"10","author":"JH Buckner","year":"2010","unstructured":"Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849\u201359.","journal-title":"Nat Rev Immunol"},{"key":"1364_CR17","doi-asserted-by":"crossref","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta Felquer M, Armstrong AW, et al. Group for research and assessment of psoriasis and psoriatic arthritis: treatment recommendations for psoriatic arthritis 2015. Arthritis Rheumatol. 2016;68:1060\u201371.","DOI":"10.1002\/art.39573"},{"key":"1364_CR18","first-page":"S104","volume":"33","author":"P Mease","year":"2015","unstructured":"Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol. 2015;33:S104\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"1364_CR19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3899\/jrheum.111125","volume":"39","author":"F Iannone","year":"2012","unstructured":"Iannone F, Lapadula G. The inhibitor of costimulation of T cells: Abatacept. J Rheumatol. 2012;39:100\u20132.","journal-title":"J Rheumatol"},{"key":"1364_CR20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","volume":"5","author":"L Moreland","year":"2006","unstructured":"Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5:185\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"1364_CR21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","volume":"378","author":"T Orban","year":"2011","unstructured":"Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412\u20139.","journal-title":"Lancet"},{"key":"1364_CR22","first-page":"2162","volume":"33","author":"MH Weisman","year":"2006","unstructured":"Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33:2162\u20136.","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"1364_CR23","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/ar1688","volume":"7","author":"EM Ruderman","year":"2005","unstructured":"Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther. 2005;7 Suppl 2:S21\u20135.","journal-title":"Arthritis Res Ther"},{"key":"1364_CR24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114\u201323.","journal-title":"N Engl J Med"},{"key":"1364_CR25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"P Mease","year":"2011","unstructured":"Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939\u201348.","journal-title":"Arthritis Rheum"},{"key":"1364_CR26","doi-asserted-by":"publisher","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017:1\u20139. doi: 10.1136\/annrheumdis-2016-210724 .","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"1364_CR27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11926-011-0181-y","volume":"13","author":"AW Kuijk van","year":"2011","unstructured":"van Kuijk AW, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep. 2011;13:353\u20139.","journal-title":"Curr Rheumatol Rep"},{"key":"1364_CR28","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"1364_CR29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59:686\u201391.","journal-title":"Arthritis Rheum"},{"key":"1364_CR30","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3899\/jrheum.110278","volume":"38","author":"LC Coates","year":"2011","unstructured":"Coates LC, Mumtaz A, Helliwell PS, Mease PJ, Callis-Duffin K, Krueger GG, et al. Development of a disease severity and responder index for psoriatic arthritis (PsA)\u2013report of the OMERACT 10 PsA special interest group. J Rheumatol. 2011;38:1496\u2013501.","journal-title":"J Rheumatol"},{"key":"1364_CR31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1364_CR32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35:745\u201357.","journal-title":"Rheum Dis Clin North Am"},{"key":"1364_CR33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2010.139550","volume":"70","author":"MG Sande van de","year":"2011","unstructured":"van de Sande MG, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini S, Codullo V, et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis. 2011;70:423\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1364_CR34","first-page":"37","volume":"17","author":"DJ Veale","year":"1999","unstructured":"Veale DJ. The role of arthroscopy in early arthritis. Clin Exp Rheumatol. 1999;17(1):37\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"1364_CR35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-59745-401-8_3","volume":"135","author":"M Gogarty","year":"2007","unstructured":"Gogarty M, Fitzgerald O. Immunohistochemistry of the inflamed synovium. Methods Mol Med. 2007;135:47\u201363.","journal-title":"Methods Mol Med"},{"key":"1364_CR36","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/ard.2005.050963","volume":"65","author":"AW Kuijk van","year":"2006","unstructured":"van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65:1551\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1364_CR37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/art.1780400206","volume":"40","author":"PP Tak","year":"1997","unstructured":"Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997;40:217\u201325.","journal-title":"Arthritis Rheum"},{"key":"1364_CR38","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/rheumatology\/kei094","volume":"44","author":"LA Rhodes","year":"2005","unstructured":"Rhodes LA, Grainger AJ, Keenan AM, Thomas C, Emery P, Conaghan PG. The validation of simple scoring methods for evaluating compartment-specific synovitis detected by MRI in knee osteoarthritis. Rheumatology (Oxford). 2005;44:1569\u201373.","journal-title":"Rheumatology (Oxford)"},{"key":"1364_CR39","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3899\/jrheum.141010","volume":"42","author":"D Glinatsi","year":"2015","unstructured":"Glinatsi D, Bird P, Gandjbakhch F, Mease PJ, Boyesen P, Peterfy CG, et al. Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the hand and foot in a randomized placebo-controlled trial. J Rheumatol. 2015;42:2473\u20139.","journal-title":"J Rheumatol"},{"key":"1364_CR40","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00262-014-1581-4","volume":"63","author":"C Devaud","year":"2014","unstructured":"Devaud C, Darcy PK, Kershaw MH. Foxp3 expression in T regulatory cells and other cell lineages. Cancer Immunol Immunother. 2014;63:869\u201376.","journal-title":"Cancer Immunol Immunother"},{"key":"1364_CR41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.clinthera.2008.03.002","volume":"30","author":"EM Massarotti","year":"2008","unstructured":"Massarotti EM. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis. Clin Ther. 2008;30:429\u201342.","journal-title":"Clin Ther"},{"key":"1364_CR42","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","volume":"73","author":"PM Meiners","year":"2014","unstructured":"Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, et al. Abatacept treatment reduces disease activity in early primary Sjogren\u2019s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73:1393\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1364_CR43","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","volume":"70","author":"IH Song","year":"2011","unstructured":"Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70:1108\u201310.","journal-title":"Ann Rheum Dis"},{"key":"1364_CR44","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","volume":"103","author":"JR Abrams","year":"1999","unstructured":"Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999;103:1243\u201352.","journal-title":"J Clin Invest"},{"key":"1364_CR45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.192.5.681","volume":"192","author":"JR Abrams","year":"2000","unstructured":"Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000;192:681\u201394.","journal-title":"J Exp Med"},{"key":"1364_CR46","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/ard.2009.113233","volume":"69","author":"JD Canete","year":"2010","unstructured":"Canete JD, Celis R, Hernandez V, Pablos JL, Sanmarti R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis. 2010;69:935\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1364_CR47","doi-asserted-by":"crossref","first-page":"R335","DOI":"10.1186\/ar1192","volume":"6","author":"D Cao","year":"2004","unstructured":"Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004;6:R335\u201346.","journal-title":"Arthritis Res Ther"},{"key":"1364_CR48","doi-asserted-by":"crossref","unstructured":"Bonelli M, Goschl L, Bluml S, Karonitsch T, Hirahara K, Ferner E, et al. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. Rheumatology (Oxford). 2016;55:710\u201320.","DOI":"10.1093\/rheumatology\/kev403"},{"key":"1364_CR49","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s10875-011-9527-5","volume":"31","author":"C Alvarez-Quiroga","year":"2011","unstructured":"Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L, Juarez-Reyes A, Monsivais-Urenda A, Baranda L, et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol. 2011;31:588\u201395.","journal-title":"J Clin Immunol"},{"key":"1364_CR50","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","volume":"67","author":"J Belasco","year":"2015","unstructured":"Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol. 2015;67:934\u201344.","journal-title":"Arthritis Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1364-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T10:30:53Z","timestamp":1569666653000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1364-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1364-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]},"article-number":"158"}}